Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

PNT

POINT Biopharma Global (PNT)

POINT Biopharma Global Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:PNT
DateTimeSourceHeadlineSymbolCompany
01/08/20247:00AMEdgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:PNTPOINT Biopharma Global Inc
01/03/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PNTPOINT Biopharma Global Inc
01/03/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PNTPOINT Biopharma Global Inc
12/27/20235:41PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PNTPOINT Biopharma Global Inc
12/27/20235:40PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PNTPOINT Biopharma Global Inc
12/27/20235:40PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PNTPOINT Biopharma Global Inc
12/27/20235:39PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PNTPOINT Biopharma Global Inc
12/27/20235:39PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PNTPOINT Biopharma Global Inc
12/27/20235:37PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PNTPOINT Biopharma Global Inc
12/27/20235:36PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PNTPOINT Biopharma Global Inc
12/27/20235:35PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PNTPOINT Biopharma Global Inc
12/27/20239:44AMEdgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:PNTPOINT Biopharma Global Inc
12/27/20239:43AMEdgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:PNTPOINT Biopharma Global Inc
12/27/20239:42AMEdgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:PNTPOINT Biopharma Global Inc
12/27/20239:41AMEdgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:PNTPOINT Biopharma Global Inc
12/27/20239:39AMEdgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:PNTPOINT Biopharma Global Inc
12/27/20238:54AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PNTPOINT Biopharma Global Inc
12/27/20238:31AMPR Newswire (US)Lilly Completes Acquisition of POINT BiopharmaNASDAQ:PNTPOINT Biopharma Global Inc
12/18/20238:14AMEdgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:PNTPOINT Biopharma Global Inc
12/18/20237:30AMGlobeNewswire Inc.Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate CancerNASDAQ:PNTPOINT Biopharma Global Inc
12/18/20236:45AMPR Newswire (US)Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 22, 2023NASDAQ:PNTPOINT Biopharma Global Inc
12/05/20236:25AMIH Market NewsMoody’s Reassesses China, GitLab Exceeds Estimates, Twilio Plans Major Layoffs, and MoreNASDAQ:PNTPOINT Biopharma Global Inc
12/04/20237:22AMEdgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:PNTPOINT Biopharma Global Inc
12/04/20236:45AMPR Newswire (US)Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 15, 2023NASDAQ:PNTPOINT Biopharma Global Inc
11/17/20237:05AMEdgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:PNTPOINT Biopharma Global Inc
11/17/20236:45AMPR Newswire (US)Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 1, 2023NASDAQ:PNTPOINT Biopharma Global Inc
11/15/20237:00AMEdgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:PNTPOINT Biopharma Global Inc
11/14/20234:33PMPR Newswire (US)Lilly Announces the Receipt of NRC Consent in Connection with its Proposed Acquisition of POINT BiopharmaNASDAQ:PNTPOINT Biopharma Global Inc
11/13/20237:30AMGlobeNewswire Inc.POINT Biopharma Reports Third Quarter 2023 Financial Results and Provides Business HighlightsNASDAQ:PNTPOINT Biopharma Global Inc
11/13/20237:15AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PNTPOINT Biopharma Global Inc
 Showing the most relevant articles for your search:NASDAQ:PNT